| Year |
Citation |
Score |
| 2017 |
Lin CW, Dutta S, Ding B, Wang T, Zadeikis N, Asatryan A, Kort J, Campbell A, Podsadecki T, Liu W. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects. Journal of Clinical Pharmacology. PMID 28800195 DOI: 10.1002/jcph.959 |
0.323 |
|
| 2017 |
Lin CW, Dutta S, Asatryan A, Wang H, Clifton J, Campbell A, Liu W. Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study. Clinical Pharmacology in Drug Development. PMID 28464496 DOI: 10.1002/cpdd.350 |
0.402 |
|
| 2016 |
Lin CW, Dutta S, Asatryan A, Chiu YL, Wang H, Clifton J, Campbell A, Liu W. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study. Journal of Pharmaceutical Sciences. PMID 27863806 DOI: 10.1016/j.xphs.2016.10.007 |
0.41 |
|
| 2015 |
Manjula BG, Bagga R, Kalra J, Dutta S. Labour induction with an intermediate-dose oxytocin regimen has advantages over a high-dose regimen. Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 35: 362-7. PMID 25384080 DOI: 10.3109/01443615.2014.968103 |
0.324 |
|
| 2014 |
An G, Liu W, Katz DA, Marek GJ, Awni W, Dutta S. Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens. Biopharmaceutics & Drug Disposition. 35: 417-29. PMID 25041811 DOI: 10.1002/bdd.1912 |
0.389 |
|
| 2014 |
Othman AA, Haig G, Florian H, Locke C, Gertsik L, Dutta S. The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers British Journal of Clinical Pharmacology. 77: 965-974. PMID 24215171 DOI: 10.1111/bcp.12281 |
0.343 |
|
| 2013 |
An G, Liu W, Katz DA, Marek G, Awni W, Dutta S. Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1035-45. PMID 23431112 DOI: 10.1124/dmd.112.049742 |
0.31 |
|
| 2013 |
Othman AA, Haig G, Florian H, Locke C, Zhang J, Dutta S. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers British Journal of Clinical Pharmacology. 75: 1299-1311. PMID 23016924 DOI: 10.1111/j.1365-2125.2012.04472.x |
0.404 |
|
| 2012 |
Othman AA, Nothaft W, Awni WM, Dutta S. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: Population analysis of data from 3 phase 1 trials Journal of Clinical Pharmacology. 52: 1028-1041. PMID 21566201 DOI: 10.1177/0091270011407497 |
0.34 |
|
| 2011 |
Othman AA, Lenz RA, Zhang J, Li J, Awni WM, Dutta S. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers. Journal of Clinical Pharmacology. 51: 512-26. PMID 20495134 DOI: 10.1177/0091270010370460 |
0.372 |
|
| 2009 |
Reed RC, Dutta S, Liu W. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy. Epilepsy Research. 87: 260-7. PMID 19892524 DOI: 10.1016/j.eplepsyres.2009.09.015 |
0.36 |
|
| 2007 |
Li J, Wang E, Dutta S, Lau JS, Jiang SW, Datta K, Mukhopadhyay D. Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux. Molecular and Cellular Biology. 27: 7345-53. PMID 17682059 DOI: 10.1128/MCB.02201-06 |
0.303 |
|
| 2007 |
Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S, Faught E. Safety of rapid intravenous loading of valproate. Epilepsia. 48: 478-83. PMID 17319914 DOI: 10.1111/J.1528-1167.2007.00989.X |
0.308 |
|
| 2004 |
Dutta S, Zhang Y, Lee LL, O'Dea R. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers. Biopharmaceutics & Drug Disposition. 25: 353-7. PMID 15378556 DOI: 10.1002/bdd.421 |
0.331 |
|
| 2003 |
Dutta S, Cloyd JC, Granneman GR, Collins SD. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Research. 53: 29-38. PMID 12576165 DOI: 10.1016/S0920-1211(02)00252-8 |
0.322 |
|
| 2002 |
Dutta S, Zhang Y, Daszkowski DJ, Granneman GR, Verlinden M. Single- and multiple-dose pharmacokinetics of fiduxosin under nonfasting conditions in healthy male subjects. Journal of Clinical Pharmacology. 42: 540-6. PMID 12017348 DOI: 10.1177/00912700222011599 |
0.388 |
|
| 2002 |
Dutta S, Zhang Y, Daszkowski DJ, Granneman GR, Verlinden M. Multiple dose pharmacokinetics of fiduxosin under fasting conditions in healthy elderly male subjects. The Journal of Pharmacy and Pharmacology. 54: 641-7. PMID 12005359 DOI: 10.1211/0022357021778952 |
0.359 |
|
| Show low-probability matches. |